FibroGen (FGEN) Competitors $0.35 -0.02 (-4.88%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. ADCT, ACRV, ACRS, IPHA, FULC, OCGN, AMRN, CYBN, LRMR, and TLSAShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include ADC Therapeutics (ADCT), Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), Innate Pharma (IPHA), Fulcrum Therapeutics (FULC), Ocugen (OCGN), Amarin (AMRN), Cybin (CYBN), Larimar Therapeutics (LRMR), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. ADC Therapeutics Acrivon Therapeutics Aclaris Therapeutics Innate Pharma Fulcrum Therapeutics Ocugen Amarin Cybin Larimar Therapeutics Tiziana Life Sciences ADC Therapeutics (NYSE:ADCT) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Is ADCT or FGEN more profitable? FibroGen has a net margin of -67.66% compared to ADC Therapeutics' net margin of -300.00%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics-300.00% N/A -61.33% FibroGen -67.66%N/A -36.17% Does the media refer more to ADCT or FGEN? In the previous week, FibroGen had 11 more articles in the media than ADC Therapeutics. MarketBeat recorded 14 mentions for FibroGen and 3 mentions for ADC Therapeutics. FibroGen's average media sentiment score of 0.79 beat ADC Therapeutics' score of 0.57 indicating that FibroGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroGen 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ADCT or FGEN? FibroGen received 286 more outperform votes than ADC Therapeutics when rated by MarketBeat users. However, 68.18% of users gave ADC Therapeutics an outperform vote while only 59.66% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformADC TherapeuticsOutperform Votes6068.18% Underperform Votes2831.82% FibroGenOutperform Votes34659.66% Underperform Votes23440.34% Which has preferable valuation & earnings, ADCT or FGEN? ADC Therapeutics has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$70.72M2.22-$240.05M-$2.39-0.68FibroGen$29.62M1.21-$284.23M-$0.48-0.74 Do analysts prefer ADCT or FGEN? ADC Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 423.08%. FibroGen has a consensus price target of $10.00, indicating a potential upside of 2,724.86%. Given FibroGen's higher probable upside, analysts plainly believe FibroGen is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, ADCT or FGEN? ADC Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Do insiders & institutionals believe in ADCT or FGEN? 41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 2.0% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryFibroGen beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.24M$7.13B$5.74B$8.28BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.307.3324.7219.36Price / Sales1.26239.38398.2493.27Price / CashN/A65.6738.1634.64Price / Book-0.206.787.154.51Net Income-$284.23M$142.41M$3.20B$247.14M7 Day Performance6.03%5.03%2.83%3.64%1 Month Performance-25.60%4.47%6.98%-2.30%1 Year Performance-86.02%-3.29%15.58%4.92% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.2351 of 5 stars$0.35-4.9%$10.00+2,749.0%-85.7%$35.42M$29.62M-0.29570Analyst ForecastADCTADC Therapeutics1.6711 of 5 stars$1.79-3.5%$8.50+376.2%-63.3%$172.59M$70.72M-0.75310ACRVAcrivon Therapeutics2.0714 of 5 stars$5.50+1.1%$23.67+330.3%-9.4%$171.25MN/A-2.0458Upcoming EarningsACRSAclaris Therapeutics2.7956 of 5 stars$1.59+1.6%$11.67+636.1%+47.8%$171.05M$18.72M-3.05100IPHAInnate Pharma2.3014 of 5 stars$2.02+0.8%$11.50+470.7%-18.4%$170.18M$24.85M0.00220Upcoming EarningsNews CoverageFULCFulcrum Therapeutics1.7073 of 5 stars$3.13+0.3%$8.63+175.6%-66.8%$168.95M$80M-10.10100Positive NewsOCGNOcugen0.9179 of 5 stars$0.57+6.8%$6.33+1,003.4%-61.1%$168.49M$4.06M-3.2180Gap UpAMRNAmarin0.3442 of 5 stars$0.41-0.9%N/A-46.0%$168.38M$228.61M-4.56360Analyst ForecastCYBNCybin2.7907 of 5 stars$7.63+0.8%$86.00+1,027.1%N/A$163.87MN/A-1.7450LRMRLarimar Therapeutics2.5137 of 5 stars$2.55-1.5%$20.13+688.6%-71.8%$163.03MN/A-2.2230Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTLSATiziana Life Sciences0.5422 of 5 stars$1.55-1.6%N/A+132.3%$162.84MN/A0.008Gap Down Remove Ads Related Companies and Tools Related Companies ADC Therapeutics Competitors Acrivon Therapeutics Competitors Aclaris Therapeutics Competitors Innate Pharma Competitors Fulcrum Therapeutics Competitors Ocugen Competitors Amarin Competitors Cybin Competitors Larimar Therapeutics Competitors Tiziana Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FGEN Stock Free FGEN Stock Alerts